BC Week In Review | Sep 15, 2014
Clinical News

C16G2: Phase II data

A double-blind, U.S. Phase II trial in about 60 healthy adults showed that a dental tray application of a gel formulation of C16G2 was superior to a mouth rinse application and a gel formulation applied...
BC Extra | Mar 17, 2014
Financial News

C3 Jian raises $60.5 million in series D

C3 Jian Inc. (Marina del Rey, Calif.) raised $60.5 million in a series D round led by existing investor Renaissance Holding Company. New investor Delta Dental also participated along with other undisclosed new and existing...
BC Week In Review | Mar 17, 2014
Clinical News

C16G2: Phase II started

C3 Jian began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate C16G2 for 7 days in about 60 healthy adults. The trial will evaluate gel and rinse applications of C16G2 administered using a dental...
BC Week In Review | Sep 2, 2013
Clinical News

C16G2: Phase I data

A double-blind, dose-escalation, U.S. Phase I trial in 36 healthy volunteers showed that a single oral rinse of C16G2 led to no treatment-related, severe or serious reported adverse events. C3 Jian Inc. , Marina del Rey,...
BC Week In Review | Feb 25, 2013
Clinical News

C16G2: Completed Phase I enrollment

C3 Jian completed enrollment of 36 healthy volunteers in a double-blind, dose-escalation, U.S. Phase I trial to evaluate a single oral rinse of C16G2. C3 Jian Inc. , Marina del Rey, Calif.   Product: C16G2  ...
BC Extra | Feb 28, 2012
Financial News

C3 Jian raises $30 million

C3 Jian Inc. (Inglewood, Calif.) raised $30 million in a series C round from existing investors Wyssta Investments; Renaissance Health Services; and Corvesta. C3 Jian plans to submit an IND to FDA in April for...
Items per page:
1 - 6 of 6